GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 601–700 of 880
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Sotani, N., Kusuhara, S., Nishisho, R., Kuno, H., Shima, H., Haruwaka, K., Mori, Y., Kishi, M., Furuyashiki, T., Kobayashi, K., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426241122 · Cited by 10
“Although the expression of GLP - 1 receptors in retinal microglia and macroglia (i.e., Müller glia and astrocytes) remains debated ( 52 ), liraglutide may alleviate the proinflammatory effects of retinal microglia through direct or indirect mechanisms ( 54 ).”
Ho, L. T., Fang, Y., Hsu, P.-S., Wang, J., & Tsai, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-19657-5 · Cited by 13
“These wide-ranging effects are believed to result from the presence of GLP-1 receptors in multiple organ systems, including the heart, kidneys, and liver 11 .”
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
“Instead, reductions in circulating NEFA following GLP1 agonism likely reflect improved insulin-mediated suppression of lipolysis [13, 61, 69, 70], potentially due to reductions in adipocyte size, improved perfusion, increased adiponectin and decreased macrophage infiltration [71–73].”
Wada, R., & Yagihashi, S. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9326-7 · Cited by 8
“The expressions of GLP1R in beta-cell [5, 6, 14] and DPP-IV in alpha-cell [10, 11] were confirmed in the current study.”
BackgroundResultLiljedahl, L., Norlin, J., McGuire, J. N., & James, P. (2017) · Physiological Reports · doi:10.14814/phy2.13187 · Cited by 7
Matić, A., Vuković, R., Heffer, M., Balog, M., Ivić, V., Gáspár, R., Ducza, E., Szűcs, K. F., Seres, A. B., Vari, S. G., et al. (2021) · Croatian Medical Journal · doi:10.3325/cmj.2021.62.215 · Cited by 7
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Kaya, E., Syn, W., & Manka, P. P. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001083 · Cited by 7
Eastwood, M. P., Kampmeijer, A., Jiménez, J., Zia, S., Vanbree, R., Verbist, G., Toelen, J., & Deprest, J. A. (2015) · Fetal Diagnosis and Therapy · doi:10.1159/000436962 · Cited by 7
Giblett, J. P., Axell, R. G., White, P. A., Aetesam‐ur‐Rahman, M., Clarke, S. J., Figg, N., Bennett, M. R., West, N. E. J., & Hoole, S. P. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.12.002 · Cited by 7
“Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.”
BackgroundGLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Rapid One-Step Capturing of Native, Cell-Free Synthesized and Membrane-Embedded GLP-1R
Haueis, L., Stech, M., Schneider, E., Lanz, T., Hebel, N., Zemella, A., & Kubick, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032808 · Cited by 7
“Unlike antibody B11, 3F52 is reported to bind to the GLP-1 binding site of the ECD, thereby acting as a competitive antagonist of native GLP-1 [44,45].”
BackgroundKaneko, S., Nishijima, K., Bosch‐Traberg, H., Kaku, K., & Seino, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12793 · Cited by 6
Giblett, J. P., & Hoole, S. P. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvw237 · Cited by 6
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
Horvit, A. M., Kaput, K. L., Neece, A., Abramowitz, J. D., Abreu, M., Ratti, G. A., Finklea, J. D., Jain, R., & Mirfakhraee, S. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.10.006 · Cited by 10
Zhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“The GLP-1 receptor is directly expressed in human cardiac sinus node cells, and GLP-1RAs activate this receptor to mediate an increased HR [40, 41].”
Saadat, S., Chow, T. G., Tang, Y., Almandoz, J. P., Messiah, S. E., & Xie, L. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.05.010 · Cited by 6
Tudurachi, B.-S., Anghel, L., Tudurachi, A., Sascău, R. A., Zanfirescu, R.-L., & Stătescu, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061314 · Cited by 7
Vozza, A., Volpe, S., Custodero, C., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Bergamasco, A., Antonica, G., Tortorella, C., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/8182211 · Cited by 9
“In addition, GLP-1 modulates in fl ammation at several sites, including the kidneys and blood vessels, where GLP-1 receptors have been mainly revealed [32] through a decrease in cAMP-PKA-dependent ROS production [37].”
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Renoprotective effects of dulaglutide in patients with T2DM and CKD
Sørensen, C. M., & Holst, J. J. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0055-x · Cited by 7
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
Chiang, C., Ueng, K., Chao, T., Lin, T., Wu, Y., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.08.003 · Cited by 7
“GLP-1 receptors are widely expressed in various CV tissues (31-33).”
BackgroundVeedfald, S., Hansen, M., Christensen, L. W., Larsen, S. A. H., Hjøllund, K. R., Plamboeck, A., Hartmann, B., Deacon, C. F., & Holst, J. J. (2016) · Experimental Physiology · doi:10.1113/ep085692 · Cited by 6
“Furthermore, using a monoclonal GLP-1 receptor antibody, the GLP-1 receptor has been identified in the myenteric plexus in the gastrointestinal tract of monkeys (Pyke et al. 2014).”
MethodThe treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
Ferrari, F., Moretti, A., & Villa, R. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105018 · Cited by 6
Badi, R. M., Khaleel, E. F., El-Bidawy, M. H., Satti, H. H., & Mostafa, D. G. (2020) · Folia Biologica · doi:10.14712/fb2020066050186 · Cited by 8
“However, GLP-1Rs are widely distributed in numerous cells and organs including the liver, hypothalamus, pancreas, kidney, heart, endothelial cells, neurons, glial cells, and immune cells (Iwai et al., 2006; Park et al., 2007; Arakawa et al., 2010; Romaní-Pérez et al., 2013; Pyke et al., 2014; Heppner et al., 2015).”
BackgroundImpact of CVOTs in primary and secondary prevention of kidney disease
Cosmo, S. D., Viazzi, F. C., Piscitelli, P. A., Leoncini, G., Mirijello, A., Bonino, B., & Pontremoli, R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107907 · Cited by 7
Hanna, A., Connelly, K. A., Josse, R. G., & McIntyre, R. S. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.972370 · Cited by 6
“Furthermore, the recent finding that myocytes within the sinoatrial node also express the GLP-1R suggests that there may be a direct effect on heart rate, over and above autonomic system modulation [21] although the significance of this finding remains unclear [22].”
BackgroundLiraglutide in Heart Failure: Caution is Needed
Michel Komajda, N. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.707 · Cited by 6
The influence of insulin and incretin-based therapies on renal tubular transport
Rosati, E., Giuseppe, G. D., Mezza, T., & Ferraro, P. M. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02048-w · Cited by 8
Watanabe, H., Fujishima, F., Yamazaki, Y., Imamura, M., Hijioka, S., Hara, K., Kuwahara, T., Yatabe, Y., Sakamoto, K., Shiga, H., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04098-2 · Cited by 6
“The immunohistochemical expression of GLP-1R has been studied using non-specific polyclonal antibodies [7]; however, in this study, we used an extensively validated monoclonal antibody (Mab3 F52) [7, 11].”
Hanna, S., Sethiadi, J., Ali, Q., & Sinha, S. (2025) · Cancers · doi:10.3390/cancers17162600 · Cited by 7
“Although canonical GLP-1R expression is not detected in the liver [29,30], GLP-1RAs benefit liver health and exert their influence on cancer risk indirectly through weight reduction, improved insulin sensitivity, and reduced hepatic lipid accumulation [31].”
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
“As the absence of GLP-1R in human C cells is proved [55], the theory of direct binding may no longer make sense.”
Potential role of glucagon like peptide 1 in taste receptors
Doval-Caballero, J. L. E., Ferreira‐Hermosillo, A., Eugenio-Ponce, G. D., García-Sáenz, M. R., Ibarra‐Salce, R., Tenorio-Rojo, A. P., Luna-Ávila, E. S., Palacios, P. C. G., Pérez-Hernández, F., Rojas-Milán, E., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1683419 · Cited by 10
Meier, M., Cummings, J. L., Abdelsaid, M. A., Feliciano, J., Eusebe, J., Stirn, H., & Coucha, M. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101282 · Cited by 7
Thomas, J., Dagan, M., Wang, B. H., Gutman, S., & Kaye, D. M. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013279 · Cited by 10
“Cardiomyocytes in the sinoatrial node are a major site of GLP-1R expression in the heart 80 , and GLP-1RA therapy consistently increases HR in clinical trials.”
Obesity and Heart Failure With Reduced Ejection Fraction
Khan, M. S., Javaid, S. S., Petrie, M. C., Zieroth, S. R., Anker, S. D., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5083 · Cited by 12
Ridge, T. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000114 · Cited by 6
“Effect of glucagon-like peptide-1 receptor agonists on pulse rate In addition to the pancreas, stomach, thyroid gland, small intestine, brain stem, and hypothalamus, the GLP-1 receptor is expressed in human sinoatrial node (SAN) myocytes (Pyke et al., 2014).”
BackgroundAdvances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
Elimihele, T. A., Mangrola, A. M., Oshomoji, O., Wilson, N., Nnamani, I., Ashong, B., Billings, S., Getu, D. K., Kumar, S., & Maliakkal, B. J. (2024) · Cureus · doi:10.7759/cureus.69152 · Cited by 6
Watanabe, T., Hiramatsu, K., Nishimura, K., & Ono, T. (2018) · The Journal of Poultry Science · doi:10.2141/jpsa.0170185 · Cited by 5
“Pyke et al. (2014) have revealed that GLP-1R is predominantly localized on B cells in monkey and human pancreases.”
BackgroundKiernan, R., Persand, D., Maddie, N., Cai, W., & Carrillo-Sepúlveda, M. A. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00031.2022 · Cited by 9
Circadian hormone secretion of enteroendocrine cells: implication on pregnancy status
Homeida, A. M., Homeida, M. A., & Al-Suhaimi, E. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1106382 · Cited by 5
“Cardiovascular system Improves endothelial function (67, 68)”
Chartoumpekis, D. V., Habeos, E. E., & Psilopanagioti, A. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100104 · Cited by 6
“A few studies have presented experimental evidence for the localization of GLP-1 receptor mRNA and protein in human hypothalamus, using in situ hybridization techniques [16,17] and immunohistochemistry [18 – 20].”
Liu, Y., Tseng, Y., Wu, Y.-H., Tong, L., Tsai, S., Huang, S., Wu, B., Lo, S., Chen, I.-C., Dai, Z., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177106 · Cited by 7
Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment
Li, X., Liu, Y., Zhang, Z., Hai, W., Pan, Y., & Zhang, Y. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07197-z · Cited by 6
“These findings are generally consistent with previous studies [15 , 16 , 17].”
Manell, E., Puuvuori, E., Svensson, A. C., Velikyan, I., Hulsart‐Billström, G., Hedenqvist, P., Holst, J. J., Jensen‐Waern, M., & Eriksson, O. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002083 · Cited by 11
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Murphy, C. F., & le Roux, C. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.06 · Cited by 4
Svane, M. S., Johannesen, H. H., Martinussen, C., Bojsen-Møller, K. N., Hansen, M. L., Hansen, A. E., Deacon, C. F., Hartmann, B., Keller, S. H., Klausen, T. L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14106 · Cited by 5
The role of GLP-1 receptor in pain disorders and its pharmacological properties
Jing, F., Zeng, Y., Yu, Q.-L., & Fu, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178345 · Cited by 6
Effects of GLP-1 receptor agonists on copeptin in euvolemic participants
Leibnitz, S., Winzeler, B. F., Refardt, J. C., Vogt, D., Sailer, C. O., & Christ‐Crain, M. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag005 · Cited by 5
Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation
Asadalizadeh, M., Rahbar, M. K. M., Mahmoudie, T., Abbasi, M., Akbari, M., Shakiba, D., Shabestari, A. M., & Ebrahimifar, M. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01411-x · Cited by 7
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
“Beyond these principal sites of GLP-1R action, lower-level receptor expression has been documented in several additional tissues, including the heart, kidney, lungs, and testis (Pyke et al., 2014; Richards et al., 2014; Caltabiano et al., 2020).”
InfluentialKim, Y. C., Meng, C., Kanoo, S., Thomson, S. C., Karihaloo, A., & Vallon, V. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00109.2026 · Cited by 4
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 5
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
“In human kidneys, GLP-1 RA settles in proximal renal tubule cells and preglomerular vascular smooth muscle cells [66].”
Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
Malbert, C., Chauvin, A., Horowitz, M., & Jones, K. L. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001540 · Cited by 4
Rico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101en · Cited by 7
“Human studies have identified its expression in proximal tubular cells and in preglomerular vascular smooth muscle cells 17 whilst in animal models, various studies have localized GLP1R in glomerular cells and the proximal portion of the proximal convoluted tubule 18,19 .”
BackgroundRole of Microneedles for Improved Treatment of Obesity: Progress and Challenges
Chilamakuri, S. N., Manasa, N., Thalla, M., Ravichandiran, V., Lee, Y., Cho, S. M., Jung, H., & Natesan, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01115 · Cited by 5
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Luca, L. D., Bilato, C., Navazio, A., Corda, M., Milli, M., Scicchitano, P., Marco, M. D., Riccio, C., Geraci, G., Iacovoni, A., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf071 · Cited by 4
Zhong, Z., Chen, K., Zhao, Y., & Xia, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9993229 · Cited by 5
Are GLP-1R agonists the long-sought-after panacea for obesity?
Dowsett, G. K. C., & Yeo, G. S. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.06.008 · Cited by 6
Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
“87 GLP-1 has also been shown to protect mouse podocytes against damage caused by high glucose by decreasing reactive oxygen species production, attenuating podocyte apoptosis, and decreasing proinflammatory cytokine secretion.”
Steyn, L. V., Ananthakrishnan, K., Anderson, M. J., Patek, R., Kelly, A. C., Vágner, J., Lynch, R. M., & Limesand, S. W. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0817-1 · Cited by 4
Mermet, M., Denom, J., Mieczkowska, A., Wery, M., Biggs, E. K., Gribble, F. M., Reimann, F., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00086.2025 · Cited by 8
“…olfactory bulb, amygdala, preoptic gland, amygdala, preoptic area, nucleus accumbens, hypothalamic arcuate nucleus, paraventricular nucleus, dorsomedial nucleus, lateral hypothalamic nucleus, supraoptic nucleus, postrema area, nucleus tractus solitarius and lateral reticular nucleus (36, 40–42).”
Tanaka, M., & Itoh, H. (2025) · International Summit on Diabetes, Endocrinology and Metabolic Disorders · doi:10.1038/s41440-025-02418-2 · Cited by 3
“One possibility of increased HR is an activation of sinoatrial node in the atrium where the localization of GLP-1 receptor is demonstrated in humans [52].”
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
Norlin, J., Dermit, M., Sidiropoulos, N., Galsgaard, E. D., Hansen, H. H., Feigh, M., Veidal, S. S., Latta, M. R., Henriksson, E., & Andersen, B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331665 · Cited by 3
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“GLP-1 receptors are expressed not only in pancreatic islets but also in the central nervous system, gastrointestinal tract, kidneys, vascular endothelium, and myocardium, enabling diverse biological actions [14].”
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 11
“It is widely expressed in tissues such as the pancreas, central nervous system, gastrointestinal tract, and cardiovascular system, highlighting its diverse physiological roles and therapeutic potential beyond glucose regulation 32,34,35 .”
GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads
O’Brien, H., Franciosi, A. N., & Butler, M. W. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001249 · Cited by 3
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
Gandhi, A., Phyu, E. M., Koom‐Dadzie, K., Dickson, K. B., & Halm, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062853 · Cited by 6
“These alterations were not observed in sleep-deprived participants maintained under dark conditions, indicating a direct effect of light rather than sleep loss alone on glu-coregulatory pathways [3].”
Samaranayake, C. B., Niglas, M., Baxan, N., Kempny, A., Ashek, A., Gatzoulis, M. Α., Price, L., Dimopoulos, K., Wilkins, M. R., Wort, S. J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202660 · Cited by 4
“Of potential relevance, increased GLP-1R expression has been demonstrated in smooth muscle cells of pulmonary arteries and arterioles (8, 9), and both native GLP-1 and synthetic GLP-1 agonists including exenatide demonstrate a vasorelaxant effect across several vascular beds, potentially mediated…”
Vyas, K. S., Gopinath, S., Dacso, M. M., Green, J. B., & Wyles, S. P. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005187 · Cited by 4
Perl, A., & Banki, K. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-026-01421-2 · Cited by 3
Morsy, M. M., Hassan, H. A., Morsi, R. M., Nafea, O. E., Farag, A. I., & Ramadan, R. S. (2024) · Reproductive Toxicology · doi:10.1016/j.reprotox.2024.108826 · Cited by 3
PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN
Bayrasheva, V. K., Babenko, A. Y., Bairamov, A. A., Чефу, С. Г., Shatalov, I. S., Pchelin, I. Y., Arefieva, A. N., & Grineva, E. N. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-3-8-16 · Cited by 4
An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide
Zhou, W., Huang, B., & Liu, M. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.219142 · Cited by 3
Vukajlovic, T., Sailer, C. O., Asmar, A., Jensen, B. L., Vogt, D., Christ‐Crain, M., & Winzeler, B. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac063 · Cited by 5
Shao, Y.-W., Tian, J., Yang, Y., Hu, Y., Zhu, Y., & Shu, Q. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.931161 · Cited by 4
Supramanian, K., Sekar, M., & Afendi, N. S. H. N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005083 · Cited by 10
Peart, L. A., Draper, M., & Tarasov, A. I. (2024) · Peptides · doi:10.1016/j.peptides.2024.171243 · Cited by 5
Song, J., Zhuang, Y., Pan, X., Chen, Y., & Xie, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35289 · Cited by 4
“Glucagon-like peptide-1 receptor (GLP-1R) belongs to the G protein-coupled receptor family and is expressed in pancreatic islets, kidneys, lungs, and endothelial cells, with high expression levels in the renovascular system and renal tubular epithelium of the kidney [8 – 11].”
BackgroundGLP-1 receptor agonists—another promising therapy for Alport syndrome?
Boeckhaus, J., Mabillard, H. R., & Sayer, J. A. (2025) · Journal of Rare Diseases · doi:10.1007/s44162-024-00065-8 · Cited by 4
“Alternatively, GLP-1 RA might directly act on renin-pro-ducing cells within the juxtaglomerular apparatus, where GLP-1 receptors have been identified or might directly protect podocytes from apoptosis [58–60].”
Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy
Teitelman, G. (2014) · Endocrinology · doi:10.1210/en.2014-1166 · Cited by 3
A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
Junker, A. E., Gluud, L. L., Pedersen, J., Langhoff, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Case Reports in Gastroenterology · doi:10.1159/000369968 · Cited by 4
Pan, Y., Lv, J., Pan, D., Xu, Y., Yang, M., Ju, H., Zhou, J., Zhu, L., Zhao, Q., & Zhang, Y. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9562-8 · Cited by 4
Automated ISH for Validated Histological Mapping of Lowly Expressed Genes
Pyke, C. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0623-0_14 · Cited by 3
Self-citationAlowaysi, M., Astro, V., Fiacco, E., Alzahrani, F., Alkuraya, F. S., & Adamo, A. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102148 · Cited by 3
“GLP1R is broadly expressed in several tissues including ßcells, cardiac myocytes, lung, kidney, stomach and heart, several brain regions (Pyke et al., 2014; Richards et al., 2014).”
BackgroundVoetmann, L. M., Rolin, B., Kirk, R. K., Knudsen, L. B., Merkestein, M., Ahnfelt‐Rønne, J., Kodal, A. L. B., Jessen, C., Ozen, A. I., Pyke, C., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70510 · Cited by 3
“9,27,28 Therefore, we investigated if the observed upregulations of the primary readout genes were restricted to Brunner’s gland cells.”
Self-citationState of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma
Gomez, D. R., Swartzman, I., Linderholm, A., Cummings, B. P., Zeki, A. A., Sundar, K. M., & Kenyon, N. J. (2025) · Lung · doi:10.1007/s00408-025-00861-z · Cited by 3
“The GLP-1 receptors are expressed in multiple organs including the stomach [60], heart [61], lung [62–66], and kidney [61, 67].”
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
In vivo functional profiling and structural characterization of the human GLP1R A316T variant
Eid, L. E., Manchanda, Y., Austin, G. O., Deane-Alder, K., Rujan, R., Mariam, Z., Oqua, A. I., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., et al. (2026) · Science Advances · doi:10.1126/sciadv.adw0899 · Cited by 9
“…drug target for the treatment of type 2 diabetes (T2D), obesity, and cardiovascular disease, is a class B1 secretin-like G protein–coupled receptor (GPCR) predominantly expressed in the pancreas but also present in other organs such as the brain, heart, stomach, intestine, and kidneys ( 1 – 3 ).”
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications
Arslan, S., & Aydin, A. (2026) · Academia oncology. · doi:10.20935/acadonco8234 · Cited by 2
The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity
Koyanagi, Y., Iigaya, K., Ikeda, K., Onimaru, H., & Izumizaki, M. (2026) · Hypertension Research · doi:10.1038/s41440-026-02633-5 · Cited by 4
“The third mechanism involves the presence of GLP-1 receptors in the sinoatrial node [46, 47], and it is proposed that GLP-1 receptor agonists may directly act on the sinoatrial node to induce tachycardia [48].”
Levi, O., Dalal, N., Komissar, A., Moldavsky, D., Khamaisi, S., Elyagon, S., Murninkas, M., Eliyahu, A., Burg, S., Attali, B., et al. (2026) · EP Europace · doi:10.1093/europace/euag091 · Cited by 3
“Our findings may fit with evidence for GLP-1R expression in atrial cardiomyocytes 35,57,58 and preclinical data demonstrating that GLP-1R activation can directly modulate cardiac metabolism, inflammation, and remodelling.”
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“186 187-189 Therefore, rather than direct genomic reprogramming of myosin heavy chain (MHC) isoforms as observed in animals, 190 the human “fiber-type transition” likely represents a functional oxidative remodeling mediated through the vascular system.”
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.